$LLY

ELI LILLY & Co

Insider trades
48
26
5
$8.3M
Zakrowski Donald A
100%
See all $LLY insider activity →
Med

This Week’s Top 5: Eli Lilly's GLP-1, Novo Nordisk and P&G

UK MHRA approved Eli Lilly’s once-daily oral GLP-1 orforglipron (Foundayo) on 10 Aug 2026 for weight loss and weight maintenance in adults meeting BMI criteria. Bristol Myers Squibb plans a US$2.3bn Houston manufacturing campus within a US$40bn US investment. Novo Nordisk hired Omnicom for US media, ending WPP, and partnered with AWS on AI drug discovery. P&G is expanding Health Care after its US$3.8bn Thorne acquisition.

Eli Lilly Sues Mounjaro, Zepbound Generics as GLP-1 Disputes Multiply

Eli Lilly filed its first U.S. patent lawsuits over generic versions of Mounjaro and Zepbound, suing 14 companies in the District of Delaware, according to the complaints. The case concerns GLP-1 related patent enforcement and could affect how generics are marketed and labeled.

Eli Lilly targets alleged black market sales of its experimental GLP

Eli Lilly sued six entities it alleges sell black market retatrutide, an investigational weight-loss GLP-1 in late-phase trials. Lilly says sellers market it as “research-use only” but intend human use, and that the drug is not approved anywhere. Lilly expects FDA submission by year end and says it referred 200+ parties to regulators and law enforcement.

LLY sentiment & insider activity

Over the past 7 days, alphai's AI scored 79 news stories mentioning LLY (ELI LILLY & Co). Coverage has skewed bullish: 48 bullish, 26 neutral, and 5 bearish.

Recent LLY coverage spans regulation, sector analysis and financial news.

In the last 30 days, LLY insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($8.3M). The most active reporter was Zakrowski Donald A, SVP, Finance, & CAO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving LLY

  • Regulatory approval in the UK expands addressable market for Lilly’s oral GLP-1, potentially improving near-term demand expectations.

    healthcare-digital.com · Aug 15, 2026

  • The suit is a direct legal overhang on generic entry timing for Lillys GLP-1 franchise, with potential near-term volatility around litigation milestones.

    law.com · Aug 14, 2026

  • Legal action and FDA stance could pressure the gray-market retatrutide supply chain and reinforce Lilly’s IP and regulatory position.

    aol.com · Aug 14, 2026

  • Legal action and FDA scrutiny around unapproved retatrutide could reduce black-market supply and reinforce brand protection, but near-term financial impact is likely limited.

    healio.com · Aug 14, 2026

  • Foundayo demand appears to be building on scripts, but reported sales disappointment and telehealth data uncertainty create a mixed near-term setup.

    fiercepharma.com · Aug 14, 2026

alphai scores every news story that mentions LLY with an AI model for sentiment and relevance, and aggregates insider trades from ELI LILLY & Co's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LLY

Score

This Week’s Top 5: Eli Lilly's GLP-1, Novo Nordisk and P&G

UK MHRA approved Eli Lilly’s once-daily oral GLP-1 orforglipron (Foundayo) on 10 Aug 2026 for weight loss and weight maintenance in adults meeting BMI criteria. Bristol Myers Squibb plans a US$2.3bn Houston manufacturing campus within a US$40bn US investment. Novo Nordisk hired Omnicom for US media, ending WPP, and partnered with AWS on AI drug discovery. P&G is expanding Health Care after its US$3.8bn Thorne acquisition.

$LLYMed

Eli Lilly targets alleged black market sales of its experimental GLP

Eli Lilly sued six entities it alleges sell black market retatrutide, an investigational weight-loss GLP-1 in late-phase trials. Lilly says sellers market it as “research-use only” but intend human use, and that the drug is not approved anywhere. Lilly expects FDA submission by year end and says it referred 200+ parties to regulators and law enforcement.

$LLYLow

Eli Lilly files lawsuits against six companies for allegedly selling retatrutide

Eli Lilly said it filed lawsuits against six companies, alleging they sell counterfeit, unapproved retatrutide, which is not FDA approved. Lilly plans to submit a biologics license application for retatrutide in Q1 2027. The company cited phase 3 results and said it has reported 200+ individuals and 14,000+ listings to regulators. The FDA also warned about illegal incretin-based drugs.

$LLYMedAI 8/10

Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

The UK Medicines and Healthcare products Regulatory Agency approved Eli Lilly’s oral weight-loss drug orforglipron (Foundayo) for weight management and type 2 diabetes, making it Europe’s first such approval, according to the regulator. The article notes Foundayo is a pill, while Novo Nordisk’s Wegovy is also a pill in the UK and has food restrictions. It cites IQVIA obesity-medicine market growth to $92B in 2026.

$LLYLow

‘Unusual’ for GLP-1 to not be listed: Lilly boss

Eli Lilly said its GLP-1 weight loss and diabetes medicine Mounjaro should be listed on Australia’s PBS at “a fair price,” while the health minister indicated talks with companies will continue. The article says negotiations were not close enough to bridge differences on pricing for Mounjaro listing.

$LLYLow

Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity

Eli Lilly (LLY) reported Q2 results driven by GLP-1 drugs Mounjaro and Zepbound. The company said about half of prescriptions are cash-paid, and average realized prices fell 13% YoY while volume rose 60%. Revenue increased 48% to $23B and adjusted EPS rose 33% to $8.38. Management expects volume growth to offset price declines.

$NVOMed

Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Novo Nordisk CEO Mike Doustdar defended the company’s lawsuit against Eli Lilly over obesity-drug advertising. The dispute cites a head-to-head trial where Zepbound (10 mg/15 mg) patients lost 20.2% body weight vs Wegovy 13.7% over 72 weeks. Novo argues older Wegovy dosing was used and cites FDA approval of higher Wegovy dose on Mar 19, 2026. Lilly said it backs its ads; Zepbound Q2 U.S. revenue rose 44% to $4.9B.

Related tickers